Adjuvant treatment following resection of stage III melanoma is standard practice, based largely on trials that showed it improves recurrence-free survival. However, oncologists have long wondered ...
Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results